HAVCR2 and neoplasm: Currently, monoclonal antibody-based high affinity checkpoint inhibitors are tested against PD1 (nivolumab; lambrolizumab; pidilizumab, pembrolizimab, MGD013), LAG-3 (MGD013), and TIM-3 (lirilumab) to support anti-tumor activity of T cells (66–68).